Drug Trial Radar · NCT02023567
Objective Diagnostic Markers and Personalized Intervention in MDD Patients
Last checked: Nov 19, 2026Latest source record: May 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,400
Planned (sponsor's estimate)
Start
Nov 2013
Primary completion
Dec 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Peking UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Capital Medical University; Peking Union Medical College Hospital; Tianjin Medical University General Hospital; Tianjin Anding Hospital; The First Hospital of Hebei Medical University; First Hospital of China Medical University; Dalian Seventh People's Hospital; The First Affiliated Hospital of Shanxi Medical University
- First posted
- Dec 30, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high recurrence rate, suicide rate and disability rate. It's reported that the global burden caused by MDD will be up to the second rank among all the disease burdens by 2020. China is also confronted with the daunting challenges against MDD. It's assessed that the monthly incidence of MDD is 6.1%, non-hospitalizing rate reaches up to 92% and the non-treatment rate is approximate 95%. However, to date, the pathogenesis of MDD is obscure and the current therapies don't work well. Therefore, it's urgent and critical to elucidate the pathogenesis of MDD, to develop early diagnostic criteria and effective intervention in MDD. Considering the diversity of weights on genetic factor and environmental factor in MDD, in this project, the investigators aim firstly to explore the effect of "genetic-environmental interaction"on the pathogeny of MDD for classifying MDD into "genetic type", "environmental type" and "others" based on a case-control study. We next conduct the neurobiological, neurocognitive and psycho-behavioral assessments among MDD, schizophrenia and healthy groups to screen the salient endophenotypes for establishing the diagnostic models of MDD . The investigators further analyse the changes of these indicators after 8 weeks'medication to select the potential predictors for therapeutic evaluations and interventional options in MDD patients. Finally, the investigators continue a 2-year follow-up study to test and verify the predictors of prognosis in MDD patients.
Conditions
- Depressive Disorder, Major
Interventions
SSRIsDrug
fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- The changes of HAMD total score at 8 weeks from baselineTime frame: week 0,2,4,8
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anding Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Active not recruiting
Peking University Sixth Hospital
Beijing, Beijing Municipality, China · Recruiting
Hebei Medical University First Hospital
Shijiazhuang, Hebei, China · Active not recruiting
Dalian Seventh People's Hospital
Dalian, Liaoning, China · Active not recruiting
First Hospital of China Medical University
Shenyang, Liaoning, China · Active not recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Active not recruiting
Tianjin Anding Hospital
Tianjin, Tianjin Municipality, China · Active not recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.